[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZWcKyxVxT1bFGf-BtvBjA3LyNlVY8WTYVufotin1W80":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"University of Cologne",[4],199,false,28,24,232786,13,116,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Hodgkin Lymphoma",9,{"name":18,"count":19},"Classical Hodgkin Lymphoma",7,{"name":21,"count":22},"Schizophrenia",6,{"name":24,"count":25},"Hyponatremia",5,{"name":27,"count":28},"Hodgkin´s Lymphoma",4,{"name":30,"count":31},"Multiple Myeloma",3,{"name":33,"count":31},"Cancer",{"name":35,"count":31},"Glaucoma",[37,42,47,51,56,61,65,70,75,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04656951","Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse","2025-03-15","Daratumumab",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04837859","Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma","2026-05","Tislelizumab",{"nctId":48,"briefTitle":49,"date":45,"intervention":50},"NCT04838652","Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","Pembrolizumab plus Chemotherapy",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06916416","Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma","2026-06","Pembrolizumab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06419179","Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin\u002FCisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)","2026-09","Durvalumab",{"nctId":62,"briefTitle":63,"date":64,"intervention":55},"NCT06045195","Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma","2027-01",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05583071","Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL","2027-02","Tafasitamab",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06919679","Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma","2028-01","BrECADD",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07280585","STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease","2030-05-15","Dapagliflozin 10 mg",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04985318","Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP","2034-12-12","Cablivi®",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,117,147,203,233,255,276,300,318,337,355,373,394,415,451,490,518,536,554,572,590,616,643,661,679,704,798,844,885,919,961,991,1021,1051,1081,1111,1143,1169,1195,1231,1267,1285,1309,1327,1352,1376,1402,1427,1452,1470,1488,1506,1531,1557,1575,1609,1631,1664,1687,1715,1740,1758,1776,1794,1812,1830,1848,1866,1892,1910,1928,1946,1971,1999,2022,2046,2069,2087,2105,2128,2146,2171,2195,2221,2239,2263,2287,2305,2333,2351,2369,2387,2405,2429,2453,2478,2504,2522,2546,2564,2587,2610,2634,2661,2685,2709,2732,2750,2775,2800,2818,2842],{"intervention":79,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":113,"NA":115},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":78},[105],{"nctId":76,"briefTitle":77,"status":106,"phases":107,"primaryCompletion":78,"completion":78,"start":108,"enrollment":109,"conditions":110,"interventions":112},"RECRUITING",[89],"2025-12-16",420,[111],"Polycystic Kidney, Autosomal Dominant",[79],{"trials":114,"activeCount":98},[],{"trials":116,"activeCount":98},[],{"intervention":55,"totalTrials":118,"cells":119},2,{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":141,"PHASE4":143,"NA":145},{"trials":121,"activeCount":98},[],{"trials":123,"activeCount":98},[],{"trials":125,"activeCount":118,"soonestReadout":54},[126,134],{"nctId":52,"briefTitle":53,"status":127,"phases":128,"primaryCompletion":54,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":133},"NOT_YET_RECRUITING",[88],"2028-06","2025-06",50,[18],[55],{"nctId":62,"briefTitle":63,"status":127,"phases":135,"primaryCompletion":64,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":140},[88],"2029-01","2025-08",40,[15],[55],{"trials":142,"activeCount":98},[],{"trials":144,"activeCount":98},[],{"trials":146,"activeCount":98},[],{"intervention":148,"totalTrials":28,"cells":149},"Rituximab",{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":185,"PHASE4":199,"NA":201},{"trials":151,"activeCount":98},[],{"trials":153,"activeCount":98},[],{"trials":155,"activeCount":94,"soonestReadout":68},[156,166,175],{"nctId":157,"briefTitle":158,"status":159,"phases":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},"NCT00147953","Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma","COMPLETED",[88],"2004-06",30,[164],"Non-Hodgkin's Lymphoma",[148],{"nctId":167,"briefTitle":168,"status":159,"phases":169,"primaryCompletion":170,"start":171,"conditions":172,"interventions":174},"NCT00346684","Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)",[88],"2007-11","2006-07",[173],"Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)",[148],{"nctId":66,"briefTitle":67,"status":106,"phases":176,"primaryCompletion":68,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},[88],"2027-04","2024-08-23",20,[181],"Non-Hodgkin Lymphoma",[69,183,148,184],"Lenalidomide","Methotrexate",{"trials":186,"activeCount":98},[187],{"nctId":188,"briefTitle":189,"status":159,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT00515554","HD18 for Advanced Stages in Hodgkins Lymphoma",[89],"2019-07","2020-07","2008-05",1500,[196],"Hodgkins Lymphoma",[148,198],"BEACOPP escalated",{"trials":200,"activeCount":98},[],{"trials":202,"activeCount":98},[],{"intervention":183,"totalTrials":118,"cells":204},{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":221,"PHASE3":227,"PHASE4":229,"NA":231},{"trials":206,"activeCount":98},[],{"trials":208,"activeCount":98},[209],{"nctId":210,"briefTitle":211,"status":159,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":162,"conditions":216,"interventions":217},"NCT01056679","Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients",[87],"2014-04","2016-02","2010-04",[15],[218,219,183,220],"Doxorubicine","DTIC","Vinblastine",{"trials":222,"activeCount":94,"soonestReadout":68},[223],{"nctId":66,"briefTitle":67,"status":106,"phases":224,"primaryCompletion":68,"completion":177,"start":178,"enrollment":179,"conditions":225,"interventions":226},[88],[181],[69,183,148,184],{"trials":228,"activeCount":98},[],{"trials":230,"activeCount":98},[],{"trials":232,"activeCount":98},[],{"intervention":41,"totalTrials":94,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":236,"activeCount":98},[],{"trials":238,"activeCount":98},[],{"trials":240,"activeCount":94,"soonestReadout":40},[241],{"nctId":38,"briefTitle":39,"status":242,"phases":243,"primaryCompletion":40,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":248},"ACTIVE_NOT_RECRUITING",[88],"2031-12","2021-06-01",67,[30],[41],{"trials":250,"activeCount":98},[],{"trials":252,"activeCount":98},[],{"trials":254,"activeCount":98},[],{"intervention":46,"totalTrials":94,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":98},[],{"trials":262,"activeCount":94,"soonestReadout":45},[263],{"nctId":43,"briefTitle":44,"status":106,"phases":264,"primaryCompletion":45,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":269},[88],"2028-05","2024-05-24",120,[18],[46],{"trials":271,"activeCount":98},[],{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":98},[],{"intervention":60,"totalTrials":94,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":98},[],{"trials":283,"activeCount":94,"soonestReadout":59},[284],{"nctId":57,"briefTitle":58,"status":285,"phases":286,"primaryCompletion":59,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"ENROLLING_BY_INVITATION",[88],"2026-12","2024-10-09",29,[291],"Small Cell Lung Carcinoma",[60,293],"Olaparib",{"trials":295,"activeCount":98},[],{"trials":297,"activeCount":98},[],{"trials":299,"activeCount":98},[],{"intervention":293,"totalTrials":94,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":312,"PHASE4":314,"NA":316},{"trials":303,"activeCount":98},[],{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":94,"soonestReadout":59},[308],{"nctId":57,"briefTitle":58,"status":285,"phases":309,"primaryCompletion":59,"completion":287,"start":288,"enrollment":289,"conditions":310,"interventions":311},[88],[291],[60,293],{"trials":313,"activeCount":98},[],{"trials":315,"activeCount":98},[],{"trials":317,"activeCount":98},[],{"intervention":50,"totalTrials":94,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":331,"PHASE4":333,"NA":335},{"trials":321,"activeCount":98},[],{"trials":323,"activeCount":98},[],{"trials":325,"activeCount":94,"soonestReadout":45},[326],{"nctId":48,"briefTitle":49,"status":106,"phases":327,"primaryCompletion":45,"completion":265,"start":328,"enrollment":289,"conditions":329,"interventions":330},[88],"2024-03-05",[18],[50],{"trials":332,"activeCount":98},[],{"trials":334,"activeCount":98},[],{"trials":336,"activeCount":98},[],{"intervention":69,"totalTrials":94,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":340,"activeCount":98},[],{"trials":342,"activeCount":98},[],{"trials":344,"activeCount":94,"soonestReadout":68},[345],{"nctId":66,"briefTitle":67,"status":106,"phases":346,"primaryCompletion":68,"completion":177,"start":178,"enrollment":179,"conditions":347,"interventions":348},[88],[181],[69,183,148,184],{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":98},[],{"trials":354,"activeCount":98},[],{"intervention":184,"totalTrials":94,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":367,"PHASE4":369,"NA":371},{"trials":358,"activeCount":98},[],{"trials":360,"activeCount":98},[],{"trials":362,"activeCount":94,"soonestReadout":68},[363],{"nctId":66,"briefTitle":67,"status":106,"phases":364,"primaryCompletion":68,"completion":177,"start":178,"enrollment":179,"conditions":365,"interventions":366},[88],[181],[69,183,148,184],{"trials":368,"activeCount":98},[],{"trials":370,"activeCount":98},[],{"trials":372,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":98},[],{"trials":380,"activeCount":94,"soonestReadout":73},[381],{"nctId":71,"briefTitle":72,"status":127,"phases":382,"primaryCompletion":73,"completion":383,"start":137,"enrollment":384,"conditions":385,"interventions":387},[88],"2030-01",35,[386],"Hodgkin Lymphoma (Category)",[74],{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"intervention":84,"totalTrials":94,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":94,"soonestReadout":83},[408],{"nctId":81,"briefTitle":82,"status":242,"phases":409,"primaryCompletion":83,"completion":83,"start":410,"enrollment":411,"conditions":412,"interventions":414},[],"2021-03-25",350,[413],"Acquired Thrombotic Thrombocytopenic Purpura",[84],{"intervention":416,"totalTrials":118,"cells":417},"Amisulpride",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":435,"PHASE4":437,"NA":449},{"trials":419,"activeCount":98},[],{"trials":421,"activeCount":98},[],{"trials":423,"activeCount":98},[424],{"nctId":425,"briefTitle":426,"status":159,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":433},"NCT00628290","Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis",[88],"2004-11","2008-03","2002-10",42,[21],[434,416],"Cannabidiol",{"trials":436,"activeCount":98},[],{"trials":438,"activeCount":98},[439],{"nctId":440,"briefTitle":441,"status":159,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT00204061","Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis",[90],"2005-06","2001-01",124,[21,447],"Psychoses",[416],{"trials":450,"activeCount":98},[],{"intervention":452,"totalTrials":118,"cells":453},"Clopidogrel",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":474,"NA":488},{"trials":455,"activeCount":98},[],{"trials":457,"activeCount":98},[],{"trials":459,"activeCount":98},[],{"trials":461,"activeCount":98},[462],{"nctId":463,"briefTitle":464,"status":159,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":472},"NCT01774838","Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome",[89],"2015-06","2014-10",49,[470,471],"Acute Coronary Syndrome","Unstable Angina",[473,452],"Prasugrel",{"trials":475,"activeCount":98},[476],{"nctId":477,"briefTitle":478,"status":159,"phases":479,"primaryCompletion":480,"completion":215,"start":481,"enrollment":482,"conditions":483,"interventions":487},"NCT01112137","Effects of Clopidogrel on Blood Pressure",[90],"2009-12","2005-01",46,[484,485,486],"Blood Pressure","Endothelial Function","Platelet Function",[452,452,452,452],{"trials":489,"activeCount":98},[],{"intervention":491,"totalTrials":94,"cells":492},"pitavastatin",{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":516},{"trials":494,"activeCount":98},[],{"trials":496,"activeCount":98},[],{"trials":498,"activeCount":98},[],{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[503],{"nctId":504,"briefTitle":505,"status":159,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":9,"conditions":509,"interventions":511},"NCT02743260","Drug Transporter Interaction Study PHENTRA_2015_KPUK",[90],"2017-12","2016-04",[510],"Healthy",[491,512,513,514,515],"Metformin","digoxin","Adefovir","sitagliptin",{"trials":517,"activeCount":98},[],{"intervention":512,"totalTrials":94,"cells":519},{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":528,"NA":534},{"trials":521,"activeCount":98},[],{"trials":523,"activeCount":98},[],{"trials":525,"activeCount":98},[],{"trials":527,"activeCount":98},[],{"trials":529,"activeCount":98},[530],{"nctId":504,"briefTitle":505,"status":159,"phases":531,"primaryCompletion":507,"completion":507,"start":508,"enrollment":9,"conditions":532,"interventions":533},[90],[510],[491,512,513,514,515],{"trials":535,"activeCount":98},[],{"intervention":513,"totalTrials":94,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":552},{"trials":539,"activeCount":98},[],{"trials":541,"activeCount":98},[],{"trials":543,"activeCount":98},[],{"trials":545,"activeCount":98},[],{"trials":547,"activeCount":98},[548],{"nctId":504,"briefTitle":505,"status":159,"phases":549,"primaryCompletion":507,"completion":507,"start":508,"enrollment":9,"conditions":550,"interventions":551},[90],[510],[491,512,513,514,515],{"trials":553,"activeCount":98},[],{"intervention":514,"totalTrials":94,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":564,"NA":570},{"trials":557,"activeCount":98},[],{"trials":559,"activeCount":98},[],{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":98},[566],{"nctId":504,"briefTitle":505,"status":159,"phases":567,"primaryCompletion":507,"completion":507,"start":508,"enrollment":9,"conditions":568,"interventions":569},[90],[510],[491,512,513,514,515],{"trials":571,"activeCount":98},[],{"intervention":515,"totalTrials":94,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":588},{"trials":575,"activeCount":98},[],{"trials":577,"activeCount":98},[],{"trials":579,"activeCount":98},[],{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[584],{"nctId":504,"briefTitle":505,"status":159,"phases":585,"primaryCompletion":507,"completion":507,"start":508,"enrollment":9,"conditions":586,"interventions":587},[90],[510],[491,512,513,514,515],{"trials":589,"activeCount":98},[],{"intervention":591,"totalTrials":94,"cells":592},"Statin Recapture Therapy",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":614},{"trials":594,"activeCount":98},[],{"trials":596,"activeCount":98},[],{"trials":598,"activeCount":98},[],{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":98},[603],{"nctId":604,"briefTitle":605,"status":159,"phases":606,"primaryCompletion":607,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT01715714","Statin Recapture Therapy Before Coronary Artery Bypass Grafting",[90],"2019-04-24","2020-09-27","2012-11-07",2630,[612],"Coronary Artery Disease",[591],{"trials":615,"activeCount":98},[],{"intervention":617,"totalTrials":94,"cells":618},"ezetimibe",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":641},{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"trials":624,"activeCount":98},[],{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[629],{"nctId":630,"briefTitle":631,"status":159,"phases":632,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":638},"NCT00317993","LDL Receptor Under Ezetimibe and Simvastatin",[90],"2004-07","2004-04",60,[637],"Healthy Men",[617,639,640],"simvastatin","ezetimibe plus simvastatin",{"trials":642,"activeCount":98},[],{"intervention":639,"totalTrials":94,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":659},{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":98},[],{"trials":650,"activeCount":98},[],{"trials":652,"activeCount":98},[],{"trials":654,"activeCount":98},[655],{"nctId":630,"briefTitle":631,"status":159,"phases":656,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":657,"interventions":658},[90],[637],[617,639,640],{"trials":660,"activeCount":98},[],{"intervention":640,"totalTrials":94,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":677},{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":98},[],{"trials":670,"activeCount":98},[],{"trials":672,"activeCount":98},[673],{"nctId":630,"briefTitle":631,"status":159,"phases":674,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":675,"interventions":676},[90],[637],[617,639,640],{"trials":678,"activeCount":98},[],{"intervention":680,"totalTrials":94,"cells":681},"Ranibizumab",{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":702},{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[],{"trials":687,"activeCount":98},[],{"trials":689,"activeCount":98},[],{"trials":691,"activeCount":98},[692],{"nctId":693,"briefTitle":694,"status":695,"phases":696,"primaryCompletion":507,"completion":507,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT01213667","Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD","UNKNOWN",[90],"2010-01",110,[700],"Macular Degeneration",[680],{"trials":703,"activeCount":98},[],{"intervention":705,"totalTrials":19,"cells":706},"Prednisone",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":766,"PHASE4":794,"NA":796},{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[713,728,741,752],{"nctId":714,"briefTitle":715,"status":159,"phases":716,"primaryCompletion":717,"start":718,"enrollment":719,"conditions":720,"interventions":721},"NCT00284271","Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma",[88],"2005-12","2004-01",65,[27],[722,723,724,705,725,726,727],"Cyclophosphamide","Adramycin","Procarbacine","Vincristine","Bleomycin","Erythropoietin beta",{"nctId":729,"briefTitle":730,"status":731,"phases":732,"primaryCompletion":733,"start":734,"conditions":735,"interventions":736},"NCT00512980","PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma","TERMINATED",[88],"2013-11","2008-08",[15],[737,738,739,740],"prednisone","vinblastine","doxorubicin","gemcitabine",{"nctId":742,"briefTitle":743,"status":159,"phases":744,"primaryCompletion":745,"start":746,"enrollment":635,"conditions":747,"interventions":749},"NCT00147875","Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma",[87,88],"2007-07","2004-03",[748],"Hodgkin's Disease",[705,220,750,751],"Doxorubicin","Gemcitabine",{"nctId":753,"briefTitle":754,"status":159,"phases":755,"primaryCompletion":756,"completion":507,"start":757,"enrollment":758,"conditions":759,"interventions":760},"NCT01569204","Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma",[88],"2014-03","2012-10",100,[15],[761,722,750,705,762,763,764,765],"Etoposide","Procarbazine","Dexamethasone","Dacarbazine","Brentuximab Vedotin",{"trials":767,"activeCount":98},[768,777,787],{"nctId":769,"briefTitle":770,"status":695,"phases":771,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":775,"interventions":776},"NCT02661503","HD21 for Advanced Stages",[89],"2022-12","2025-09","2016-07",[18],[726,761,750,722,725,762,705,765,764,763],{"nctId":778,"briefTitle":779,"status":159,"phases":780,"primaryCompletion":781,"start":782,"enrollment":783,"conditions":784,"interventions":785},"NCT00264953","HD11 for Intermediate Stages",[89],"2003-01","1998-05",1395,[27],[786,726,220,219,761,762,705,725],"Adriamycin",{"nctId":788,"briefTitle":789,"status":159,"phases":790,"start":791,"conditions":792,"interventions":793},"NCT00265031","HD12 for Advanced Stages",[89],"1999-01",[27],[722,786,761,762,705,725,726],{"trials":795,"activeCount":98},[],{"trials":797,"activeCount":98},[],{"intervention":220,"totalTrials":22,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":808,"PHASE3":827,"PHASE4":840,"NA":842},{"trials":801,"activeCount":98},[],{"trials":803,"activeCount":98},[804],{"nctId":210,"briefTitle":211,"status":159,"phases":805,"primaryCompletion":213,"completion":214,"start":215,"enrollment":162,"conditions":806,"interventions":807},[87],[15],[218,219,183,220],{"trials":809,"activeCount":98},[810,814,823],{"nctId":729,"briefTitle":730,"status":731,"phases":811,"primaryCompletion":733,"start":734,"conditions":812,"interventions":813},[88],[15],[737,738,739,740],{"nctId":815,"briefTitle":816,"status":159,"phases":817,"primaryCompletion":818,"completion":818,"start":819,"enrollment":698,"conditions":820,"interventions":821},"NCT03004833","Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma",[88],"2022-08-22","2017-02-21",[18],[822,786,220,764],"Nivolumab",{"nctId":742,"briefTitle":743,"status":159,"phases":824,"primaryCompletion":745,"start":746,"enrollment":635,"conditions":825,"interventions":826},[87,88],[748],[705,220,750,751],{"trials":828,"activeCount":98},[829,833],{"nctId":778,"briefTitle":779,"status":159,"phases":830,"primaryCompletion":781,"start":782,"enrollment":783,"conditions":831,"interventions":832},[89],[27],[786,726,220,219,761,762,705,725],{"nctId":834,"briefTitle":835,"status":159,"phases":836,"primaryCompletion":781,"start":782,"enrollment":837,"conditions":838,"interventions":839},"NCT00265018","HD10 for Early Stages",[89],1370,[27],[786,726,220,219],{"trials":841,"activeCount":98},[],{"trials":843,"activeCount":98},[],{"intervention":722,"totalTrials":25,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":871,"PHASE4":881,"NA":883},{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":98},[],{"trials":851,"activeCount":98},[852,863,867],{"nctId":853,"briefTitle":854,"status":159,"phases":855,"primaryCompletion":856,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":862},"NCT01283776","Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation",[88],"2013-12","2014-06","2011-03",11,[30,861,748],"Non-Hodgkin-Lymphoma",[722],{"nctId":714,"briefTitle":715,"status":159,"phases":864,"primaryCompletion":717,"start":718,"enrollment":719,"conditions":865,"interventions":866},[88],[27],[722,723,724,705,725,726,727],{"nctId":753,"briefTitle":754,"status":159,"phases":868,"primaryCompletion":756,"completion":507,"start":757,"enrollment":758,"conditions":869,"interventions":870},[88],[15],[761,722,750,705,762,763,764,765],{"trials":872,"activeCount":98},[873,877],{"nctId":769,"briefTitle":770,"status":695,"phases":874,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":875,"interventions":876},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"nctId":788,"briefTitle":789,"status":159,"phases":878,"start":791,"conditions":879,"interventions":880},[89],[27],[722,786,761,762,705,725,726],{"trials":882,"activeCount":98},[],{"trials":884,"activeCount":98},[],{"intervention":726,"totalTrials":25,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":897,"PHASE4":915,"NA":917},{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":98},[],{"trials":892,"activeCount":98},[893],{"nctId":714,"briefTitle":715,"status":159,"phases":894,"primaryCompletion":717,"start":718,"enrollment":719,"conditions":895,"interventions":896},[88],[27],[722,723,724,705,725,726,727],{"trials":898,"activeCount":98},[899,903,907,911],{"nctId":769,"briefTitle":770,"status":695,"phases":900,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":901,"interventions":902},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"nctId":778,"briefTitle":779,"status":159,"phases":904,"primaryCompletion":781,"start":782,"enrollment":783,"conditions":905,"interventions":906},[89],[27],[786,726,220,219,761,762,705,725],{"nctId":788,"briefTitle":789,"status":159,"phases":908,"start":791,"conditions":909,"interventions":910},[89],[27],[722,786,761,762,705,725,726],{"nctId":834,"briefTitle":835,"status":159,"phases":912,"primaryCompletion":781,"start":782,"enrollment":837,"conditions":913,"interventions":914},[89],[27],[786,726,220,219],{"trials":916,"activeCount":98},[],{"trials":918,"activeCount":98},[],{"intervention":765,"totalTrials":28,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":925,"PHASE3":951,"PHASE4":957,"NA":959},{"trials":922,"activeCount":98},[],{"trials":924,"activeCount":98},[],{"trials":926,"activeCount":98},[927,937,947],{"nctId":928,"briefTitle":929,"status":159,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":935},"NCT02191930","Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma",[88],"2022-03-16","2015-09",70,[15],[936,765],"B-CAP",{"nctId":938,"briefTitle":939,"status":159,"phases":940,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":946},"NCT03652441","Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma",[88],"2023-08-10","2025-01-25","2019-11-13",14,[18],[765],{"nctId":753,"briefTitle":754,"status":159,"phases":948,"primaryCompletion":756,"completion":507,"start":757,"enrollment":758,"conditions":949,"interventions":950},[88],[15],[761,722,750,705,762,763,764,765],{"trials":952,"activeCount":98},[953],{"nctId":769,"briefTitle":770,"status":695,"phases":954,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":955,"interventions":956},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"intervention":725,"totalTrials":28,"cells":962},{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":973,"PHASE4":987,"NA":989},{"trials":964,"activeCount":98},[],{"trials":966,"activeCount":98},[],{"trials":968,"activeCount":98},[969],{"nctId":714,"briefTitle":715,"status":159,"phases":970,"primaryCompletion":717,"start":718,"enrollment":719,"conditions":971,"interventions":972},[88],[27],[722,723,724,705,725,726,727],{"trials":974,"activeCount":98},[975,979,983],{"nctId":769,"briefTitle":770,"status":695,"phases":976,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":977,"interventions":978},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"nctId":778,"briefTitle":779,"status":159,"phases":980,"primaryCompletion":781,"start":782,"enrollment":783,"conditions":981,"interventions":982},[89],[27],[786,726,220,219,761,762,705,725],{"nctId":788,"briefTitle":789,"status":159,"phases":984,"start":791,"conditions":985,"interventions":986},[89],[27],[722,786,761,762,705,725,726],{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":98},[],{"intervention":750,"totalTrials":28,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":1011,"PHASE4":1017,"NA":1019},{"trials":994,"activeCount":98},[],{"trials":996,"activeCount":98},[],{"trials":998,"activeCount":98},[999,1003,1007],{"nctId":729,"briefTitle":730,"status":731,"phases":1000,"primaryCompletion":733,"start":734,"conditions":1001,"interventions":1002},[88],[15],[737,738,739,740],{"nctId":742,"briefTitle":743,"status":159,"phases":1004,"primaryCompletion":745,"start":746,"enrollment":635,"conditions":1005,"interventions":1006},[87,88],[748],[705,220,750,751],{"nctId":753,"briefTitle":754,"status":159,"phases":1008,"primaryCompletion":756,"completion":507,"start":757,"enrollment":758,"conditions":1009,"interventions":1010},[88],[15],[761,722,750,705,762,763,764,765],{"trials":1012,"activeCount":98},[1013],{"nctId":769,"briefTitle":770,"status":695,"phases":1014,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":1015,"interventions":1016},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"intervention":761,"totalTrials":28,"cells":1022},{"EARLY_PHASE1":1023,"PHASE1":1025,"PHASE2":1027,"PHASE3":1033,"PHASE4":1047,"NA":1049},{"trials":1024,"activeCount":98},[],{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":98},[1029],{"nctId":753,"briefTitle":754,"status":159,"phases":1030,"primaryCompletion":756,"completion":507,"start":757,"enrollment":758,"conditions":1031,"interventions":1032},[88],[15],[761,722,750,705,762,763,764,765],{"trials":1034,"activeCount":98},[1035,1039,1043],{"nctId":769,"briefTitle":770,"status":695,"phases":1036,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":1037,"interventions":1038},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"nctId":778,"briefTitle":779,"status":159,"phases":1040,"primaryCompletion":781,"start":782,"enrollment":783,"conditions":1041,"interventions":1042},[89],[27],[786,726,220,219,761,762,705,725],{"nctId":788,"briefTitle":789,"status":159,"phases":1044,"start":791,"conditions":1045,"interventions":1046},[89],[27],[722,786,761,762,705,725,726],{"trials":1048,"activeCount":98},[],{"trials":1050,"activeCount":98},[],{"intervention":762,"totalTrials":28,"cells":1052},{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1063,"PHASE4":1077,"NA":1079},{"trials":1054,"activeCount":98},[],{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[1059],{"nctId":753,"briefTitle":754,"status":159,"phases":1060,"primaryCompletion":756,"completion":507,"start":757,"enrollment":758,"conditions":1061,"interventions":1062},[88],[15],[761,722,750,705,762,763,764,765],{"trials":1064,"activeCount":98},[1065,1069,1073],{"nctId":769,"briefTitle":770,"status":695,"phases":1066,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":1067,"interventions":1068},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"nctId":778,"briefTitle":779,"status":159,"phases":1070,"primaryCompletion":781,"start":782,"enrollment":783,"conditions":1071,"interventions":1072},[89],[27],[786,726,220,219,761,762,705,725],{"nctId":788,"briefTitle":789,"status":159,"phases":1074,"start":791,"conditions":1075,"interventions":1076},[89],[27],[722,786,761,762,705,725,726],{"trials":1078,"activeCount":98},[],{"trials":1080,"activeCount":98},[],{"intervention":786,"totalTrials":28,"cells":1082},{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1087,"PHASE3":1093,"PHASE4":1107,"NA":1109},{"trials":1084,"activeCount":98},[],{"trials":1086,"activeCount":98},[],{"trials":1088,"activeCount":98},[1089],{"nctId":815,"briefTitle":816,"status":159,"phases":1090,"primaryCompletion":818,"completion":818,"start":819,"enrollment":698,"conditions":1091,"interventions":1092},[88],[18],[822,786,220,764],{"trials":1094,"activeCount":98},[1095,1099,1103],{"nctId":778,"briefTitle":779,"status":159,"phases":1096,"primaryCompletion":781,"start":782,"enrollment":783,"conditions":1097,"interventions":1098},[89],[27],[786,726,220,219,761,762,705,725],{"nctId":788,"briefTitle":789,"status":159,"phases":1100,"start":791,"conditions":1101,"interventions":1102},[89],[27],[722,786,761,762,705,725,726],{"nctId":834,"briefTitle":835,"status":159,"phases":1104,"primaryCompletion":781,"start":782,"enrollment":837,"conditions":1105,"interventions":1106},[89],[27],[786,726,220,219],{"trials":1108,"activeCount":98},[],{"trials":1110,"activeCount":98},[],{"intervention":763,"totalTrials":31,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1133,"PHASE4":1139,"NA":1141},{"trials":1114,"activeCount":98},[],{"trials":1116,"activeCount":98},[],{"trials":1118,"activeCount":98},[1119,1129],{"nctId":1120,"briefTitle":1121,"status":731,"phases":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1127},"NCT00148018","Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma",[88],"2005-03",37,[1126],"Hodgkin Disease",[1128,763],"Bortezomib",{"nctId":753,"briefTitle":754,"status":159,"phases":1130,"primaryCompletion":756,"completion":507,"start":757,"enrollment":758,"conditions":1131,"interventions":1132},[88],[15],[761,722,750,705,762,763,764,765],{"trials":1134,"activeCount":98},[1135],{"nctId":769,"briefTitle":770,"status":695,"phases":1136,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":1137,"interventions":1138},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":98},[],{"intervention":219,"totalTrials":31,"cells":1144},{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1153,"PHASE3":1155,"PHASE4":1165,"NA":1167},{"trials":1146,"activeCount":98},[],{"trials":1148,"activeCount":98},[1149],{"nctId":210,"briefTitle":211,"status":159,"phases":1150,"primaryCompletion":213,"completion":214,"start":215,"enrollment":162,"conditions":1151,"interventions":1152},[87],[15],[218,219,183,220],{"trials":1154,"activeCount":98},[],{"trials":1156,"activeCount":98},[1157,1161],{"nctId":778,"briefTitle":779,"status":159,"phases":1158,"primaryCompletion":781,"start":782,"enrollment":783,"conditions":1159,"interventions":1160},[89],[27],[786,726,220,219,761,762,705,725],{"nctId":834,"briefTitle":835,"status":159,"phases":1162,"primaryCompletion":781,"start":782,"enrollment":837,"conditions":1163,"interventions":1164},[89],[27],[786,726,220,219],{"trials":1166,"activeCount":98},[],{"trials":1168,"activeCount":98},[],{"intervention":764,"totalTrials":31,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1185,"PHASE4":1191,"NA":1193},{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":98},[],{"trials":1176,"activeCount":98},[1177,1181],{"nctId":815,"briefTitle":816,"status":159,"phases":1178,"primaryCompletion":818,"completion":818,"start":819,"enrollment":698,"conditions":1179,"interventions":1180},[88],[18],[822,786,220,764],{"nctId":753,"briefTitle":754,"status":159,"phases":1182,"primaryCompletion":756,"completion":507,"start":757,"enrollment":758,"conditions":1183,"interventions":1184},[88],[15],[761,722,750,705,762,763,764,765],{"trials":1186,"activeCount":98},[1187],{"nctId":769,"briefTitle":770,"status":695,"phases":1188,"primaryCompletion":772,"completion":773,"start":774,"enrollment":194,"conditions":1189,"interventions":1190},[89],[18],[726,761,750,722,725,762,705,765,764,763],{"trials":1192,"activeCount":98},[],{"trials":1194,"activeCount":98},[],{"intervention":1196,"totalTrials":118,"cells":1197},"Fentanyl",{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1216,"PHASE4":1227,"NA":1229},{"trials":1199,"activeCount":98},[],{"trials":1201,"activeCount":98},[],{"trials":1203,"activeCount":98},[1204],{"nctId":1205,"briefTitle":1206,"status":159,"phases":1207,"primaryCompletion":1208,"completion":1209,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1214},"NCT04635852","Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients",[88],"2014-11","2014-12","2013-03",10,[33,1213],"Dyspnea, Paroxysmal",[1196,1215],"Immediate release morphine",{"trials":1217,"activeCount":98},[1218],{"nctId":1219,"briefTitle":1220,"status":159,"phases":1221,"primaryCompletion":215,"completion":215,"start":1222,"enrollment":9,"conditions":1223,"interventions":1225},"NCT00419601","Rapip Study: Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants",[89],"2006-11",[1224],"Mechanical Ventilation",[1226,1196],"Remifentanyl",{"trials":1228,"activeCount":98},[],{"trials":1230,"activeCount":98},[],{"intervention":1232,"totalTrials":118,"cells":1233},"ABVD",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1263,"NA":1265},{"trials":1235,"activeCount":98},[],{"trials":1237,"activeCount":98},[],{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[1242,1252],{"nctId":1243,"briefTitle":1244,"status":695,"phases":1245,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1251},"NCT00736320","HD16 for Early Stage Hodgkin Lymphoma",[89],"2018-09","2021-12","2009-11",1150,[15],[1232],{"nctId":1253,"briefTitle":1254,"status":159,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1261},"NCT01356680","HD17 for Intermediate Stage Hodgkin Lymphoma",[89],"2020-03-21","2020-03-23","2012-01-13",1100,[15],[1262,1232],"BEACOPPescalated",{"trials":1264,"activeCount":98},[],{"trials":1266,"activeCount":98},[],{"intervention":1226,"totalTrials":94,"cells":1268},{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1281,"NA":1283},{"trials":1270,"activeCount":98},[],{"trials":1272,"activeCount":98},[],{"trials":1274,"activeCount":98},[],{"trials":1276,"activeCount":98},[1277],{"nctId":1219,"briefTitle":1220,"status":159,"phases":1278,"primaryCompletion":215,"completion":215,"start":1222,"enrollment":9,"conditions":1279,"interventions":1280},[89],[1224],[1226,1196],{"trials":1282,"activeCount":98},[],{"trials":1284,"activeCount":98},[],{"intervention":1286,"totalTrials":94,"cells":1287},"vardenafil",{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1305,"NA":1307},{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[],{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[1296],{"nctId":1297,"briefTitle":1298,"status":159,"phases":1299,"primaryCompletion":1300,"completion":215,"start":1222,"enrollment":1301,"conditions":1302,"interventions":1304},"NCT01291199","Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome",[88,89],"2009-08",57,[1303],"Raynaud Syndrome",[1286],{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[],{"intervention":198,"totalTrials":94,"cells":1310},{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1317,"PHASE4":1323,"NA":1325},{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[],{"trials":1318,"activeCount":98},[1319],{"nctId":188,"briefTitle":189,"status":159,"phases":1320,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":1321,"interventions":1322},[89],[196],[148,198],{"trials":1324,"activeCount":98},[],{"trials":1326,"activeCount":98},[],{"intervention":1328,"totalTrials":94,"cells":1329},"voriconazole",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1348,"NA":1350},{"trials":1331,"activeCount":98},[],{"trials":1333,"activeCount":98},[],{"trials":1335,"activeCount":98},[],{"trials":1337,"activeCount":98},[1338],{"nctId":1339,"briefTitle":1340,"status":731,"phases":1341,"completion":1342,"start":1343,"enrollment":1344,"conditions":1345,"interventions":1347},"NCT00152594","Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia",[89],"2006-01","2004-10",150,[1346],"Leukemia, Myelocytic, Acute",[1328],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"intervention":1353,"totalTrials":94,"cells":1354},"Oxcarbazepine",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1372,"NA":1374},{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":98},[1363],{"nctId":1364,"briefTitle":1365,"status":159,"phases":1366,"primaryCompletion":1367,"completion":1368,"start":633,"enrollment":1369,"conditions":1370,"interventions":1371},"NCT00637234","Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia",[88,89],"2008-04","2008-07",54,[21],[1353],{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[],{"intervention":1377,"totalTrials":94,"cells":1378},"isoniazid",{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1398,"NA":1400},{"trials":1380,"activeCount":98},[],{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[1387],{"nctId":1388,"briefTitle":1389,"status":731,"phases":1390,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1397},"NCT00571753","Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)",[89],"2011-12","2012-02","2008-06",900,[1396],"Pulmonary Tuberculosis",[1377,1377],{"trials":1399,"activeCount":98},[],{"trials":1401,"activeCount":98},[],{"intervention":1403,"totalTrials":94,"cells":1404},"moxifloxacin",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1423,"NA":1425},{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"trials":1410,"activeCount":98},[],{"trials":1412,"activeCount":98},[1413],{"nctId":1414,"briefTitle":1415,"status":159,"phases":1416,"primaryCompletion":1417,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1422},"NCT00398411","Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells",[89],"2008-12","2006-10",66,[1126,181,30,1421],"Bacteremia",[1403],{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[],{"intervention":1428,"totalTrials":94,"cells":1429},"Lopinavir\u002FRitonavir plus Lamivudine\u002FZidovudine",{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1448,"NA":1450},{"trials":1431,"activeCount":98},[],{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[1438],{"nctId":1439,"briefTitle":1440,"status":159,"phases":1441,"primaryCompletion":1417,"completion":1417,"start":791,"enrollment":1442,"conditions":1443,"interventions":1446},"NCT00966160","CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes",[89],215,[1444,1445],"Acquired Immunodeficiency Syndrome","HIV Infections",[1428,1447],"Efavirenz plus Lamivudine\u002FZidovudine",{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[],{"intervention":1447,"totalTrials":94,"cells":1453},{"EARLY_PHASE1":1454,"PHASE1":1456,"PHASE2":1458,"PHASE3":1460,"PHASE4":1466,"NA":1468},{"trials":1455,"activeCount":98},[],{"trials":1457,"activeCount":98},[],{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":98},[1462],{"nctId":1439,"briefTitle":1440,"status":159,"phases":1463,"primaryCompletion":1417,"completion":1417,"start":791,"enrollment":1442,"conditions":1464,"interventions":1465},[89],[1444,1445],[1428,1447],{"trials":1467,"activeCount":98},[],{"trials":1469,"activeCount":98},[],{"intervention":473,"totalTrials":94,"cells":1471},{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1476,"PHASE3":1478,"PHASE4":1484,"NA":1486},{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[1480],{"nctId":463,"briefTitle":464,"status":159,"phases":1481,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":1482,"interventions":1483},[89],[470,471],[473,452],{"trials":1485,"activeCount":98},[],{"trials":1487,"activeCount":98},[],{"intervention":1262,"totalTrials":94,"cells":1489},{"EARLY_PHASE1":1490,"PHASE1":1492,"PHASE2":1494,"PHASE3":1496,"PHASE4":1502,"NA":1504},{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[],{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[1498],{"nctId":1253,"briefTitle":1254,"status":159,"phases":1499,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1500,"interventions":1501},[89],[15],[1262,1232],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[],{"intervention":1507,"totalTrials":94,"cells":1508},"Alkaline citrate",{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1527,"NA":1529},{"trials":1510,"activeCount":98},[],{"trials":1512,"activeCount":98},[],{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":98},[1517],{"nctId":1518,"briefTitle":1519,"status":159,"phases":1520,"primaryCompletion":1521,"completion":1521,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1526},"NCT00249951","Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants",[89],"2008-11","2005-11",80,[1525],"Nephrocalcinosis",[1507],{"trials":1528,"activeCount":98},[],{"trials":1530,"activeCount":98},[],{"intervention":1532,"totalTrials":94,"cells":1533},"Cycles N8, N5 and N6",{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1553,"NA":1555},{"trials":1535,"activeCount":98},[],{"trials":1537,"activeCount":98},[],{"trials":1539,"activeCount":98},[],{"trials":1541,"activeCount":98},[1542],{"nctId":1543,"briefTitle":1544,"status":159,"phases":1545,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1551},"NCT03042429","Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients",[89],"2016-12-31","2007-01-01",360,[1550],"Neuroblastoma",[1532,1552],"Cycles N5 and N6",{"trials":1554,"activeCount":98},[],{"trials":1556,"activeCount":98},[],{"intervention":1552,"totalTrials":94,"cells":1558},{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1565,"PHASE4":1571,"NA":1573},{"trials":1560,"activeCount":98},[],{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[1567],{"nctId":1543,"briefTitle":1544,"status":159,"phases":1568,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":1569,"interventions":1570},[89],[1550],[1532,1552],{"trials":1572,"activeCount":98},[],{"trials":1574,"activeCount":98},[],{"intervention":1576,"totalTrials":118,"cells":1577},"Everolimus",{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1579,"activeCount":98},[],{"trials":1581,"activeCount":98},[],{"trials":1583,"activeCount":98},[1584,1594],{"nctId":1585,"briefTitle":1586,"status":159,"phases":1587,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1592},"NCT01453504","Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma",[87,88],"2019-03","2012-08",73,[15],[1593,1576],"DHAP",{"nctId":1595,"briefTitle":1596,"status":159,"phases":1597,"primaryCompletion":191,"completion":1598,"start":508,"enrollment":1599,"conditions":1600,"interventions":1602},"NCT02812940","Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT",[88],"2020-12",19,[1601],"Graft-versus-Host Disease",[1576],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[],{"trials":1608,"activeCount":98},[],{"intervention":740,"totalTrials":118,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1612,"activeCount":98},[],{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[1617,1621],{"nctId":729,"briefTitle":730,"status":731,"phases":1618,"primaryCompletion":733,"start":734,"conditions":1619,"interventions":1620},[88],[15],[737,738,739,740],{"nctId":742,"briefTitle":743,"status":159,"phases":1622,"primaryCompletion":745,"start":746,"enrollment":635,"conditions":1623,"interventions":1624},[87,88],[748],[705,220,750,751],{"trials":1626,"activeCount":98},[],{"trials":1628,"activeCount":98},[],{"trials":1630,"activeCount":98},[],{"intervention":1632,"totalTrials":118,"cells":1633},"DZIF-10c",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1658,"PHASE4":1660,"NA":1662},{"trials":1635,"activeCount":98},[],{"trials":1637,"activeCount":98},[],{"trials":1639,"activeCount":98},[1640,1650],{"nctId":1641,"briefTitle":1642,"status":731,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":1645,"enrollment":1646,"conditions":1647,"interventions":1649},"NCT04631705","SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation",[87,88],"2021-09-23","2020-12-14",45,[1648],"SARS-CoV-2 Infection",[1632,1632],{"nctId":1651,"briefTitle":1652,"status":159,"phases":1653,"primaryCompletion":1654,"completion":1654,"start":1655,"enrollment":1301,"conditions":1656,"interventions":1657},"NCT04631666","SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion",[87,88],"2021-08-11","2020-12-08",[1648],[1632],{"trials":1659,"activeCount":98},[],{"trials":1661,"activeCount":98},[],{"trials":1663,"activeCount":98},[],{"intervention":1665,"totalTrials":94,"cells":1666},"Ofatumumab",{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1668,"activeCount":98},[],{"trials":1670,"activeCount":98},[],{"trials":1672,"activeCount":98},[1673],{"nctId":1674,"briefTitle":1675,"status":159,"phases":1676,"primaryCompletion":733,"completion":932,"start":1677,"enrollment":8,"conditions":1678,"interventions":1680},"NCT01187303","Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)",[88],"2011-05",[1679],"Relapsed NLPHL",[1665],{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[],{"intervention":1688,"totalTrials":94,"cells":1689},"Crizotinib",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1709,"PHASE4":1711,"NA":1713},{"trials":1691,"activeCount":98},[],{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[1696],{"nctId":1697,"briefTitle":1698,"status":159,"phases":1699,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":1704,"interventions":1708},"NCT02183870","EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer",[88],"2018-07-24","2020-02-29","2014-05",34,[1705,1706,1707],"Lung Cancer","Adenocarcinoma","NSCLC",[1688],{"trials":1710,"activeCount":98},[],{"trials":1712,"activeCount":98},[],{"trials":1714,"activeCount":98},[],{"intervention":1716,"totalTrials":94,"cells":1717},"Furosemide",{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1722,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1719,"activeCount":98},[],{"trials":1721,"activeCount":98},[],{"trials":1723,"activeCount":98},[1724],{"nctId":1725,"briefTitle":1726,"status":159,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":179,"conditions":1730,"interventions":1732},"NCT01407848","Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea",[88],"2015-07","2012-01",[1731],"Transient Tachypnoea of the Newborn",[1716,1733],"Saline 0,9%",{"trials":1735,"activeCount":98},[],{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":98},[],{"intervention":1733,"totalTrials":94,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":98},[],{"trials":1745,"activeCount":98},[],{"trials":1747,"activeCount":98},[1748],{"nctId":1725,"briefTitle":1726,"status":159,"phases":1749,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":179,"conditions":1750,"interventions":1751},[88],[1731],[1716,1733],{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"intervention":936,"totalTrials":94,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[],{"trials":1765,"activeCount":98},[1766],{"nctId":928,"briefTitle":929,"status":159,"phases":1767,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":1768,"interventions":1769},[88],[15],[936,765],{"trials":1771,"activeCount":98},[],{"trials":1773,"activeCount":98},[],{"trials":1775,"activeCount":98},[],{"intervention":1593,"totalTrials":94,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1779,"activeCount":98},[],{"trials":1781,"activeCount":98},[],{"trials":1783,"activeCount":98},[1784],{"nctId":1585,"briefTitle":1586,"status":159,"phases":1785,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":1786,"interventions":1787},[87,88],[15],[1593,1576],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"intervention":723,"totalTrials":94,"cells":1795},{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1797,"activeCount":98},[],{"trials":1799,"activeCount":98},[],{"trials":1801,"activeCount":98},[1802],{"nctId":714,"briefTitle":715,"status":159,"phases":1803,"primaryCompletion":717,"start":718,"enrollment":719,"conditions":1804,"interventions":1805},[88],[27],[722,723,724,705,725,726,727],{"trials":1807,"activeCount":98},[],{"trials":1809,"activeCount":98},[],{"trials":1811,"activeCount":98},[],{"intervention":724,"totalTrials":94,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1815,"activeCount":98},[],{"trials":1817,"activeCount":98},[],{"trials":1819,"activeCount":98},[1820],{"nctId":714,"briefTitle":715,"status":159,"phases":1821,"primaryCompletion":717,"start":718,"enrollment":719,"conditions":1822,"interventions":1823},[88],[27],[722,723,724,705,725,726,727],{"trials":1825,"activeCount":98},[],{"trials":1827,"activeCount":98},[],{"trials":1829,"activeCount":98},[],{"intervention":727,"totalTrials":94,"cells":1831},{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1842,"PHASE4":1844,"NA":1846},{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[1838],{"nctId":714,"briefTitle":715,"status":159,"phases":1839,"primaryCompletion":717,"start":718,"enrollment":719,"conditions":1840,"interventions":1841},[88],[27],[722,723,724,705,725,726,727],{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[],{"intervention":1128,"totalTrials":94,"cells":1849},{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1851,"activeCount":98},[],{"trials":1853,"activeCount":98},[],{"trials":1855,"activeCount":98},[1856],{"nctId":1120,"briefTitle":1121,"status":731,"phases":1857,"start":1123,"enrollment":1124,"conditions":1858,"interventions":1859},[88],[1126],[1128,763],{"trials":1861,"activeCount":98},[],{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[],{"intervention":1867,"totalTrials":94,"cells":1868},"Erlotinib, Bevacizumab",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1886,"PHASE4":1888,"NA":1890},{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[],{"trials":1874,"activeCount":98},[1875],{"nctId":1876,"briefTitle":1877,"status":159,"phases":1878,"primaryCompletion":757,"completion":1879,"start":697,"enrollment":138,"conditions":1880,"interventions":1882},"NCT01047059","Molecular Imaging With Erlotinib and Bevacizumab",[88],"2016-05",[1881],"Non-Small-Cell Lung Carcinoma",[1867,1883,1884,1885],"Fluoro-D-glucose","Fluoro-L-thymidine","Gadolinium-DPTA",{"trials":1887,"activeCount":98},[],{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[],{"intervention":1883,"totalTrials":94,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1895,"activeCount":98},[],{"trials":1897,"activeCount":98},[],{"trials":1899,"activeCount":98},[1900],{"nctId":1876,"briefTitle":1877,"status":159,"phases":1901,"primaryCompletion":757,"completion":1879,"start":697,"enrollment":138,"conditions":1902,"interventions":1903},[88],[1881],[1867,1883,1884,1885],{"trials":1905,"activeCount":98},[],{"trials":1907,"activeCount":98},[],{"trials":1909,"activeCount":98},[],{"intervention":1884,"totalTrials":94,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[1918],{"nctId":1876,"briefTitle":1877,"status":159,"phases":1919,"primaryCompletion":757,"completion":1879,"start":697,"enrollment":138,"conditions":1920,"interventions":1921},[88],[1881],[1867,1883,1884,1885],{"trials":1923,"activeCount":98},[],{"trials":1925,"activeCount":98},[],{"trials":1927,"activeCount":98},[],{"intervention":1885,"totalTrials":94,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1931,"activeCount":98},[],{"trials":1933,"activeCount":98},[],{"trials":1935,"activeCount":98},[1936],{"nctId":1876,"briefTitle":1877,"status":159,"phases":1937,"primaryCompletion":757,"completion":1879,"start":697,"enrollment":138,"conditions":1938,"interventions":1939},[88],[1881],[1867,1883,1884,1885],{"trials":1941,"activeCount":98},[],{"trials":1943,"activeCount":98},[],{"trials":1945,"activeCount":98},[],{"intervention":1947,"totalTrials":94,"cells":1948},"Ruxolitinib",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[1955],{"nctId":1956,"briefTitle":1957,"status":159,"phases":1958,"primaryCompletion":1959,"completion":1959,"start":1960,"enrollment":1961,"conditions":1962,"interventions":1964},"NCT02164500","JAK-inhibition in Recurrent Classical Hodgkin Lymphoma",[88],"2019-05-17","2015-10",12,[1963],"Recurrent Classical Hodgkin Lymphoma",[1947],{"trials":1966,"activeCount":98},[],{"trials":1968,"activeCount":98},[],{"trials":1970,"activeCount":98},[],{"intervention":1972,"totalTrials":94,"cells":1973},"nal-irinotecan",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[1980],{"nctId":1981,"briefTitle":1982,"status":695,"phases":1983,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1344,"conditions":1987,"interventions":1992},"NCT04617457","Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas",[88],"2024-12-31","2025-09-30","2021-10-10",[1988,1989,1990,1991],"Pancreatic Cancer","Metastasis","Surgery","Oligometastatic Disease",[1972],{"trials":1994,"activeCount":98},[],{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"intervention":2000,"totalTrials":94,"cells":2001},"caspofungin",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2016,"PHASE4":2018,"NA":2020},{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[2008],{"nctId":2009,"briefTitle":2010,"status":159,"phases":2011,"primaryCompletion":2012,"completion":2012,"start":1418,"enrollment":482,"conditions":2013,"interventions":2015},"NCT00404092","Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis",[88],"2009-10",[2014],"Invasive Aspergillosis",[2000],{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":98},[],{"trials":2021,"activeCount":98},[],{"intervention":2023,"totalTrials":94,"cells":2024},"Vitamin B 6",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2040,"PHASE4":2042,"NA":2044},{"trials":2026,"activeCount":98},[],{"trials":2028,"activeCount":98},[],{"trials":2030,"activeCount":98},[2031],{"nctId":2032,"briefTitle":2033,"status":159,"phases":2034,"primaryCompletion":2035,"completion":2035,"start":2036,"enrollment":1961,"conditions":2037,"interventions":2039},"NCT01281878","Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate",[88],"2012-09","2010-12",[2038],"Primary Hyperoxaluria Type I",[2023],{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":98},[],{"trials":2045,"activeCount":98},[],{"intervention":2047,"totalTrials":94,"cells":2048},"8 cycles BEACOPPesc plus oral contraceptive",{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"trials":2054,"activeCount":98},[2055],{"nctId":2056,"briefTitle":2057,"status":159,"phases":2058,"primaryCompletion":2059,"completion":2059,"start":718,"enrollment":635,"conditions":2060,"interventions":2061},"NCT01014507","Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma",[88],"2009-09",[196],[2047,2062],"8 cycles BEACOPPesc plus Goserelin",{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[],{"intervention":2062,"totalTrials":94,"cells":2070},{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2072,"activeCount":98},[],{"trials":2074,"activeCount":98},[],{"trials":2076,"activeCount":98},[2077],{"nctId":2056,"briefTitle":2057,"status":159,"phases":2078,"primaryCompletion":2059,"completion":2059,"start":718,"enrollment":635,"conditions":2079,"interventions":2080},[88],[196],[2047,2062],{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"intervention":822,"totalTrials":94,"cells":2088},{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2099,"PHASE4":2101,"NA":2103},{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[2095],{"nctId":815,"briefTitle":816,"status":159,"phases":2096,"primaryCompletion":818,"completion":818,"start":819,"enrollment":698,"conditions":2097,"interventions":2098},[88],[18],[822,786,220,764],{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[],{"intervention":2106,"totalTrials":94,"cells":2107},"Cannabidiol\u002FPlacebo",{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2112,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[2114],{"nctId":2115,"briefTitle":2116,"status":159,"phases":2117,"primaryCompletion":429,"completion":1368,"start":2118,"enrollment":289,"conditions":2119,"interventions":2121},"NCT00309413","A Clinical Trial on the Antipsychotic Properties of Cannabidiol",[88],"2006-03",[21,2120],"Psychotic Disorders",[2106],{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[],{"intervention":1215,"totalTrials":94,"cells":2129},{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2134,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2131,"activeCount":98},[],{"trials":2133,"activeCount":98},[],{"trials":2135,"activeCount":98},[2136],{"nctId":1205,"briefTitle":1206,"status":159,"phases":2137,"primaryCompletion":1208,"completion":1209,"start":1210,"enrollment":1211,"conditions":2138,"interventions":2139},[88],[33,1213],[1196,1215],{"trials":2141,"activeCount":98},[],{"trials":2143,"activeCount":98},[],{"trials":2145,"activeCount":98},[],{"intervention":2147,"totalTrials":94,"cells":2148},"Oxaliplatin, Capecitabine, Bevacizumab, Imatinib",{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2165,"PHASE4":2167,"NA":2169},{"trials":2150,"activeCount":98},[],{"trials":2152,"activeCount":98},[],{"trials":2154,"activeCount":98},[2155],{"nctId":2156,"briefTitle":2157,"status":159,"phases":2158,"primaryCompletion":2159,"completion":2160,"start":1367,"enrollment":2161,"conditions":2162,"interventions":2164},"NCT00784446","First-line Therapy of Stage IV Colorectal Cancer",[87,88],"2010-08","2012-12",51,[2163],"Stage IV Colorectal Cancer",[2147],{"trials":2166,"activeCount":98},[],{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"intervention":2172,"totalTrials":94,"cells":2173},"Ibrutinib",{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2189,"PHASE4":2191,"NA":2193},{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[],{"trials":2179,"activeCount":98},[2180],{"nctId":2181,"briefTitle":2182,"status":159,"phases":2183,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":944,"conditions":2186,"interventions":2188},"NCT02626884","Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)",[88],"2020-08","2016-08",[2187],"Nodular Lymphocyte-Predominant Hodgkin's Lymphoma",[2172],{"trials":2190,"activeCount":98},[],{"trials":2192,"activeCount":98},[],{"trials":2194,"activeCount":98},[],{"intervention":2196,"totalTrials":94,"cells":2197},"Durvalumab 50 MG\u002FML",{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2215,"PHASE4":2217,"NA":2219},{"trials":2199,"activeCount":98},[],{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[2204],{"nctId":2205,"briefTitle":2206,"status":695,"phases":2207,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":2210,"conditions":2211,"interventions":2213},"NCT04159974","RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus",[88],"2024-06","2019-09-30",56,[2212],"Esophageal Adenocarcinoma",[2196,2214],"Tremelimumab",{"trials":2216,"activeCount":98},[],{"trials":2218,"activeCount":98},[],{"trials":2220,"activeCount":98},[],{"intervention":2214,"totalTrials":94,"cells":2222},{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[2229],{"nctId":2205,"briefTitle":2206,"status":695,"phases":2230,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":2210,"conditions":2231,"interventions":2232},[88],[2212],[2196,2214],{"trials":2234,"activeCount":98},[],{"trials":2236,"activeCount":98},[],{"trials":2238,"activeCount":98},[],{"intervention":2240,"totalTrials":94,"cells":2241},"Denosumab",{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2243,"activeCount":98},[],{"trials":2245,"activeCount":98},[],{"trials":2247,"activeCount":98},[2248],{"nctId":2249,"briefTitle":2250,"status":159,"phases":2251,"primaryCompletion":2252,"completion":2252,"start":2253,"enrollment":1211,"conditions":2254,"interventions":2256},"NCT01799798","Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab",[88],"2015-01","2013-02",[2255],"Osteogenesis Imperfecta",[2240],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[],{"trials":2262,"activeCount":98},[],{"intervention":2264,"totalTrials":94,"cells":2265},"Dupilumab 300Mg Solution for",{"EARLY_PHASE1":2266,"PHASE1":2268,"PHASE2":2270,"PHASE3":2281,"PHASE4":2283,"NA":2285},{"trials":2267,"activeCount":98},[],{"trials":2269,"activeCount":98},[],{"trials":2271,"activeCount":98},[2272],{"nctId":2273,"briefTitle":2274,"status":159,"phases":2275,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":1646,"conditions":2278,"interventions":2280},"NCT04200755","Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma",[88],"2023-11-30","2020-05-19",[2279],"Localized Scleroderma",[2264],{"trials":2282,"activeCount":98},[],{"trials":2284,"activeCount":98},[],{"trials":2286,"activeCount":98},[],{"intervention":434,"totalTrials":94,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2299,"PHASE4":2301,"NA":2303},{"trials":2290,"activeCount":98},[],{"trials":2292,"activeCount":98},[],{"trials":2294,"activeCount":98},[2295],{"nctId":425,"briefTitle":426,"status":159,"phases":2296,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":2297,"interventions":2298},[88],[21],[434,416],{"trials":2300,"activeCount":98},[],{"trials":2302,"activeCount":98},[],{"trials":2304,"activeCount":98},[],{"intervention":2306,"totalTrials":94,"cells":2307},"antibody ch14.18",{"EARLY_PHASE1":2308,"PHASE1":2310,"PHASE2":2312,"PHASE3":2327,"PHASE4":2329,"NA":2331},{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[],{"trials":2313,"activeCount":98},[2314],{"nctId":2315,"briefTitle":2316,"status":731,"phases":2317,"primaryCompletion":2318,"completion":2319,"start":2320,"enrollment":31,"conditions":2321,"interventions":2322},"NCT02641782","NB2013-HR German (GPOH) \u002F Dutch (DCOG) Trial",[88],"2016-12-23","2017-01-30","2015-11",[1550],[2306,2323,2324,2325,2326],"GM-CSF","IL-2 i.v.","IL-2 s.c.","Retinoic acid",{"trials":2328,"activeCount":98},[],{"trials":2330,"activeCount":98},[],{"trials":2332,"activeCount":98},[],{"intervention":2323,"totalTrials":94,"cells":2334},{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2345,"PHASE4":2347,"NA":2349},{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[2341],{"nctId":2315,"briefTitle":2316,"status":731,"phases":2342,"primaryCompletion":2318,"completion":2319,"start":2320,"enrollment":31,"conditions":2343,"interventions":2344},[88],[1550],[2306,2323,2324,2325,2326],{"trials":2346,"activeCount":98},[],{"trials":2348,"activeCount":98},[],{"trials":2350,"activeCount":98},[],{"intervention":2324,"totalTrials":94,"cells":2352},{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2363,"PHASE4":2365,"NA":2367},{"trials":2354,"activeCount":98},[],{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[2359],{"nctId":2315,"briefTitle":2316,"status":731,"phases":2360,"primaryCompletion":2318,"completion":2319,"start":2320,"enrollment":31,"conditions":2361,"interventions":2362},[88],[1550],[2306,2323,2324,2325,2326],{"trials":2364,"activeCount":98},[],{"trials":2366,"activeCount":98},[],{"trials":2368,"activeCount":98},[],{"intervention":2325,"totalTrials":94,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2381,"PHASE4":2383,"NA":2385},{"trials":2372,"activeCount":98},[],{"trials":2374,"activeCount":98},[],{"trials":2376,"activeCount":98},[2377],{"nctId":2315,"briefTitle":2316,"status":731,"phases":2378,"primaryCompletion":2318,"completion":2319,"start":2320,"enrollment":31,"conditions":2379,"interventions":2380},[88],[1550],[2306,2323,2324,2325,2326],{"trials":2382,"activeCount":98},[],{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"intervention":2326,"totalTrials":94,"cells":2388},{"EARLY_PHASE1":2389,"PHASE1":2391,"PHASE2":2393,"PHASE3":2399,"PHASE4":2401,"NA":2403},{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[2395],{"nctId":2315,"briefTitle":2316,"status":731,"phases":2396,"primaryCompletion":2318,"completion":2319,"start":2320,"enrollment":31,"conditions":2397,"interventions":2398},[88],[1550],[2306,2323,2324,2325,2326],{"trials":2400,"activeCount":98},[],{"trials":2402,"activeCount":98},[],{"trials":2404,"activeCount":98},[],{"intervention":2406,"totalTrials":94,"cells":2407},"CTL019",{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2423,"PHASE4":2425,"NA":2427},{"trials":2409,"activeCount":98},[],{"trials":2411,"activeCount":98},[],{"trials":2413,"activeCount":98},[2414],{"nctId":2415,"briefTitle":2416,"status":731,"phases":2417,"primaryCompletion":2418,"completion":2418,"start":2419,"enrollment":31,"conditions":2420,"interventions":2422},"NCT04161118","TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma",[88],"2023-02-24","2021-05-12",[2421],"Non Hodgkin Lymphoma",[2406],{"trials":2424,"activeCount":98},[],{"trials":2426,"activeCount":98},[],{"trials":2428,"activeCount":98},[],{"intervention":2430,"totalTrials":94,"cells":2431},"AFM13",{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2436,"PHASE3":2447,"PHASE4":2449,"NA":2451},{"trials":2433,"activeCount":98},[],{"trials":2435,"activeCount":98},[],{"trials":2437,"activeCount":98},[2438],{"nctId":2439,"briefTitle":2440,"status":159,"phases":2441,"primaryCompletion":2442,"completion":192,"start":2443,"enrollment":2444,"conditions":2445,"interventions":2446},"NCT02321592","GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma",[88],"2019-11","2015-05",23,[15],[2430],{"trials":2448,"activeCount":98},[],{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":98},[],{"intervention":2454,"totalTrials":94,"cells":2455},"metronomic therapy",{"EARLY_PHASE1":2456,"PHASE1":2458,"PHASE2":2460,"PHASE3":2472,"PHASE4":2474,"NA":2476},{"trials":2457,"activeCount":98},[],{"trials":2459,"activeCount":98},[],{"trials":2461,"activeCount":98},[2462],{"nctId":2463,"briefTitle":2464,"status":159,"phases":2465,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":2468,"conditions":2469,"interventions":2471},"NCT02641314","Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma",[88],"2023-06-29","2016-12-22",18,[2470],"Recurrent Neuroblastoma",[2454],{"trials":2473,"activeCount":98},[],{"trials":2475,"activeCount":98},[],{"trials":2477,"activeCount":98},[],{"intervention":2479,"totalTrials":94,"cells":2480},"EGF816",{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2496,"PHASE3":2498,"PHASE4":2500,"NA":2502},{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[2485],{"nctId":2486,"briefTitle":2487,"status":159,"phases":2488,"primaryCompletion":2489,"completion":2490,"start":2491,"enrollment":2468,"conditions":2492,"interventions":2494},"NCT03516214","EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations",[87],"2022-09-30","2023-11-27","2018-04-25",[2493],"Bronchial Neoplasms",[2479,2495],"Trametinib",{"trials":2497,"activeCount":98},[],{"trials":2499,"activeCount":98},[],{"trials":2501,"activeCount":98},[],{"trials":2503,"activeCount":98},[],{"intervention":2495,"totalTrials":94,"cells":2505},{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2514,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2507,"activeCount":98},[],{"trials":2509,"activeCount":98},[2510],{"nctId":2486,"briefTitle":2487,"status":159,"phases":2511,"primaryCompletion":2489,"completion":2490,"start":2491,"enrollment":2468,"conditions":2512,"interventions":2513},[87],[2493],[2479,2495],{"trials":2515,"activeCount":98},[],{"trials":2517,"activeCount":98},[],{"trials":2519,"activeCount":98},[],{"trials":2521,"activeCount":98},[],{"intervention":2523,"totalTrials":94,"cells":2524},"Genetically modified T cells # 1138",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2538,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[2529],{"nctId":2530,"briefTitle":2531,"status":695,"phases":2532,"enrollment":2533,"conditions":2534,"interventions":2537},"NCT01645293","Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides",[87],15,[2535,2536],"CD30 Positive Cutaneous T Cell Lymphoma","CD30 Positive Transformed Mycosis Fungoides",[2523],{"trials":2539,"activeCount":98},[],{"trials":2541,"activeCount":98},[],{"trials":2543,"activeCount":98},[],{"trials":2545,"activeCount":98},[],{"intervention":218,"totalTrials":94,"cells":2547},{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2556,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[2552],{"nctId":210,"briefTitle":211,"status":159,"phases":2553,"primaryCompletion":213,"completion":214,"start":215,"enrollment":162,"conditions":2554,"interventions":2555},[87],[15],[218,219,183,220],{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[],{"trials":2563,"activeCount":98},[],{"intervention":2565,"totalTrials":94,"cells":2566},"Everolimus + BIBF 1120",{"EARLY_PHASE1":2567,"PHASE1":2569,"PHASE2":2579,"PHASE3":2581,"PHASE4":2583,"NA":2585},{"trials":2568,"activeCount":98},[],{"trials":2570,"activeCount":98},[2571],{"nctId":2572,"briefTitle":2573,"status":159,"phases":2574,"primaryCompletion":467,"completion":1879,"start":2575,"enrollment":2468,"conditions":2576,"interventions":2578},"NCT01349296","BIBF 1120 and RAD001 in Solid Tumors - Phase I",[87],"2012-07",[2577],"Solid Tumors",[2565],{"trials":2580,"activeCount":98},[],{"trials":2582,"activeCount":98},[],{"trials":2584,"activeCount":98},[],{"trials":2586,"activeCount":98},[],{"intervention":2588,"totalTrials":94,"cells":2589},"sunitinib",{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2602,"PHASE3":2604,"PHASE4":2606,"NA":2608},{"trials":2591,"activeCount":98},[],{"trials":2593,"activeCount":98},[2594],{"nctId":2595,"briefTitle":2596,"status":159,"phases":2597,"primaryCompletion":2598,"completion":2598,"start":2599,"enrollment":1961,"conditions":2600,"interventions":2601},"NCT00904657","An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers",[87],"2009-04","2008-10",[484],[2588],{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[],{"trials":2607,"activeCount":98},[],{"trials":2609,"activeCount":98},[],{"intervention":2611,"totalTrials":94,"cells":2612},"dark chocolate",{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2626,"PHASE3":2628,"PHASE4":2630,"NA":2632},{"trials":2614,"activeCount":98},[],{"trials":2616,"activeCount":98},[2617],{"nctId":2618,"briefTitle":2619,"status":159,"phases":2620,"completion":2621,"start":481,"enrollment":2622,"conditions":2623,"interventions":2625},"NCT00421499","Effects of Cocoa Intake on Blood Pressure in Elderly Individuals With Mild Hypertension",[87],"2005-05",44,[2624],"Hypertension",[2611],{"trials":2627,"activeCount":98},[],{"trials":2629,"activeCount":98},[],{"trials":2631,"activeCount":98},[],{"trials":2633,"activeCount":98},[],{"intervention":2635,"totalTrials":94,"cells":2636},"Combination of sorafenib and everolimus",{"EARLY_PHASE1":2637,"PHASE1":2639,"PHASE2":2653,"PHASE3":2655,"PHASE4":2657,"NA":2659},{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[2641],{"nctId":2642,"briefTitle":2643,"status":159,"phases":2644,"primaryCompletion":2645,"completion":2646,"start":2647,"enrollment":2648,"conditions":2649,"interventions":2652},"NCT00933777","SORAVE - Sorafenib and Everolimus in Solid Tumors",[87],"2014-02","2015-02","2009-07",36,[2650,2651],"Unspecified Adult Solid Tumor, Protocol Specific","Non-Small Cell Lung Cancer",[2635],{"trials":2654,"activeCount":98},[],{"trials":2656,"activeCount":98},[],{"trials":2658,"activeCount":98},[],{"trials":2660,"activeCount":98},[],{"intervention":2662,"totalTrials":94,"cells":2663},"Curosurf",{"EARLY_PHASE1":2664,"PHASE1":2666,"PHASE2":2668,"PHASE3":2670,"PHASE4":2672,"NA":2674},{"trials":2665,"activeCount":98},[],{"trials":2667,"activeCount":98},[],{"trials":2669,"activeCount":98},[],{"trials":2671,"activeCount":98},[],{"trials":2673,"activeCount":98},[],{"trials":2675,"activeCount":98},[2676],{"nctId":2677,"briefTitle":2678,"status":159,"phases":2679,"primaryCompletion":2680,"completion":2680,"start":2598,"enrollment":2681,"conditions":2682,"interventions":2684},"NCT00751959","Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants \u003C 27 Weeks",[91],"2012-06",213,[2683],"Respiratory Distress Syndrome, Newborn",[2662,2662],{"intervention":2686,"totalTrials":94,"cells":2687},"Acetazolamide for glaucoma patients to lower eye pressure",{"EARLY_PHASE1":2688,"PHASE1":2690,"PHASE2":2692,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2689,"activeCount":98},[],{"trials":2691,"activeCount":98},[],{"trials":2693,"activeCount":98},[],{"trials":2695,"activeCount":98},[],{"trials":2697,"activeCount":98},[],{"trials":2699,"activeCount":98},[2700],{"nctId":2701,"briefTitle":2702,"status":159,"phases":2703,"primaryCompletion":2704,"completion":1392,"start":2705,"conditions":2706,"interventions":2708},"NCT01274039","Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide",[],"2011-02","2009-02",[2707],"Control of Elevated Eye Pressure by Local and Systemic Therapy",[2686],{"intervention":2710,"totalTrials":94,"cells":2711},"Glucose 20%",{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2718,"PHASE4":2720,"NA":2722},{"trials":2713,"activeCount":98},[],{"trials":2715,"activeCount":98},[],{"trials":2717,"activeCount":98},[],{"trials":2719,"activeCount":98},[],{"trials":2721,"activeCount":98},[],{"trials":2723,"activeCount":98},[2724],{"nctId":2725,"briefTitle":2726,"status":695,"phases":2727,"primaryCompletion":480,"completion":2036,"start":2599,"enrollment":138,"conditions":2728,"interventions":2730},"NCT00761059","Analgesic Efficacy of Oral Glucose in Preterm Neonates During Suctioning",[91],[2729],"Analgesia",[2710,2731],"Aqua",{"intervention":2731,"totalTrials":94,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2735,"activeCount":98},[],{"trials":2737,"activeCount":98},[],{"trials":2739,"activeCount":98},[],{"trials":2741,"activeCount":98},[],{"trials":2743,"activeCount":98},[],{"trials":2745,"activeCount":98},[2746],{"nctId":2725,"briefTitle":2726,"status":695,"phases":2747,"primaryCompletion":480,"completion":2036,"start":2599,"enrollment":138,"conditions":2748,"interventions":2749},[91],[2729],[2710,2731],{"intervention":2751,"totalTrials":94,"cells":2752},"Technozyme",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2754,"activeCount":98},[],{"trials":2756,"activeCount":98},[],{"trials":2758,"activeCount":98},[],{"trials":2760,"activeCount":98},[],{"trials":2762,"activeCount":98},[],{"trials":2764,"activeCount":98},[2765],{"nctId":2766,"briefTitle":2767,"status":695,"phases":2768,"primaryCompletion":2769,"completion":2770,"start":2771,"enrollment":758,"conditions":2772,"interventions":2774},"NCT02373267","Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)",[],"2017-02","2019-02","2015-03",[2773],"Thrombotic Microangiopathies",[2751],{"intervention":2776,"totalTrials":94,"cells":2777},"caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2779,"activeCount":98},[],{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":98},[],{"trials":2787,"activeCount":98},[],{"trials":2789,"activeCount":98},[2790],{"nctId":2791,"briefTitle":2792,"status":159,"phases":2793,"primaryCompletion":2794,"completion":2794,"start":466,"enrollment":2795,"conditions":2796,"interventions":2798},"NCT02515526","Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein",[91],"2015-08-27",16,[2797],"AOD Effects and Consequences",[2776,2799],"ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses",{"intervention":2799,"totalTrials":94,"cells":2801},{"EARLY_PHASE1":2802,"PHASE1":2804,"PHASE2":2806,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2803,"activeCount":98},[],{"trials":2805,"activeCount":98},[],{"trials":2807,"activeCount":98},[],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[],{"trials":2813,"activeCount":98},[2814],{"nctId":2791,"briefTitle":2792,"status":159,"phases":2815,"primaryCompletion":2794,"completion":2794,"start":466,"enrollment":2795,"conditions":2816,"interventions":2817},[91],[2797],[2776,2799],{"intervention":2819,"totalTrials":94,"cells":2820},"telephone-assisted CPR",{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2825,"PHASE3":2827,"PHASE4":2829,"NA":2831},{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[],{"trials":2826,"activeCount":98},[],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[2833],{"nctId":2834,"briefTitle":2835,"status":159,"phases":2836,"primaryCompletion":2837,"completion":2837,"start":2838,"enrollment":1344,"conditions":2839,"interventions":2841},"NCT03527771","Video-assisted Telephone CPR With the EmergencyEye-Software - a Pilot Study",[91],"2018-08-28","2018-08-08",[2840],"Cardiac Arrest",[2819],{"intervention":2843,"totalTrials":94,"cells":2844},"Cablivi",{"EARLY_PHASE1":2845,"PHASE1":2847,"PHASE2":2849,"PHASE3":2851,"PHASE4":2853,"NA":2855},{"trials":2846,"activeCount":98},[],{"trials":2848,"activeCount":98},[],{"trials":2850,"activeCount":98},[],{"trials":2852,"activeCount":98},[],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[2857],{"nctId":2858,"briefTitle":2859,"status":159,"phases":2860,"primaryCompletion":2861,"completion":2861,"start":2862,"enrollment":2863,"conditions":2864,"interventions":2865},"NCT05876221","Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura",[],"2025-03-30","2023-10-30",223,[413],[2843]]